drugset / Trial / NCT05051865

To Explore the Efficacy and Safety of Camrelizumab Combined With SHR1020 in the Treatment of Advanced Melanoma

NCT05051865

Phase 2 Unknown 60 enrolled Peking University Cancer Hospital & Institute
NaSingle-groupOpen-labelTreatment

Summary

This study is being conducted to explore the efficacy and safety of camrelizumab combined with SHR1020 in the treatment of advanced melanoma.

Timeline

Start
2021-10-09
Primary completion
2024-08-30
Completion
2024-08-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Camrelizumab Monoclonal antibody
Subject Famitinib Small molecule

Indications